Close

Trending

Survival data firms up Trodelvy prospects in new breast cancer use

UK first to approve Moderna’s Omicron booster jab

Evidence-backed VR therapy helps patients overcome phobias

Strike three for Novartis’ canakinumab as lung cancer therapy

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

Accelerated Access Review

uk-life-sciences-industrail-strategy

News/ UK & Europe

Strategy for post-Brexit life science sector unveiled

Richard Staines Accelerated Access Review, Brexit, market access, policy, politics, UK life sciences industrial strategy 0 Comment

Plan aims to solve long-standing issue of access to medicines

X

Strategy for post-Brexit life science sector unveiled

https://pharmaphorum.com/news/uk-government-unveils-life-sciences-strategy/

NHS Building

Digital and Social Media/ News/ UK & Europe

New funding to improve NHS tech adoption

Marco Ricci Accelerated Access Review, digital health, NHS 0 Comment

New £86 million fund aims to speed up patient access to innovative digital technologies.

X

New funding to improve NHS tech adoption

https://pharmaphorum.com/news/new-funding-aims-improve-nhs-tech-adoption/

NHS Building

News/ UK & Europe

Disappointment as government delays pharma-friendly policies

Richard Staines Accelerated Access Review, NICE, policy, regulation 0 Comment

Proposals fall short of ambitions of Accelerated Access Review.

X

Disappointment as government delays pharma-friendly policies

https://pharmaphorum.com/news/disappointment-accelerated-access-review/

All European Union flags in front of parliament eu

Brexit/ News/ UK & Europe

UK must draw up post-Brexit pharma strategy

Richard Staines Accelerated Access Review, Brexit, finance, market access, NICE, policy 0 Comment

Big pharma could take its money elsewhere post Brexit, report warns.

X

UK must draw up post-Brexit pharma strategy

https://pharmaphorum.com/news/uk-pharma-industrial-strategy-brexit/

pangaloshres

AstraZeneca/ News/ UK & Europe

Big pharma could leave UK – AZ’s Pangalos

Richard Staines Accelerated Access Review, AstraZeneca, cancer, lung cancer, NICE, R&D 0 Comment

Last week saw the publication of the UK’s Accelerated Access Review, containing proposals to cut four years from the

X

Big pharma could leave UK – AZ’s Pangalos

https://pharmaphorum.com/news/big-pharma-leave-uk-azs-pangalos/

DNA sequence

News/ UK & Europe

UK aims to cut four years from drug development process

Richard Staines Accelerated Access Review, cost-effectiveness, NICE, pricing, regulation, reimbursement, Wellcome Trust 0 Comment

NICE, regulator and NHS should work together, according to review.

X

UK aims to cut four years from drug development process

https://pharmaphorum.com/news/uk-aims-cut-four-years-drug-development-process/

Hugh_Taylor 1

Pharma Market Access/ Sales and Marketing/ UK & Europe/ Views and analysis

Accelerated Access Review: no panacea for UK pharma

Andrew McConaghie AAR, Accelerated Access Review, market access, NHS England, UK 0 Comment

What can the AAR do for the UK pharma industry, the health service and patients?

X

Accelerated Access Review: no panacea for UK pharma

https://pharmaphorum.com/views-and-analysis/accelerated-access-review-no-panacea-uk-pharma/

NICE-logo_16-9

Articles/ Pharma Market Access/ Views and analysis

Accelerating health technologies with NICE Office for Market Access

Linda Banks Accelerated Access Review, market access, NICE 0 Comment

England’s health watchdog launched its service to speed the delivery of new technologies in October 2015. Policy coordinator

X

Accelerating health technologies with NICE Office for Market Access

https://pharmaphorum.com/articles/accelerating-health-technologies-with-nice-office-for-market-access/

Keytruda 100mg/4mL Vial and Carton

Articles/ UK & Europe/ Views and analysis

Early access initiatives – one year on

Leela Barham Accelerated Access Review, Leela Barham 0 Comment

Both the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) launched new

X

Early access initiatives – one year on

https://pharmaphorum.com/articles/early-access-initiatives-one-year-on/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com